EPHA2 Specific Neutra™ Antibody Products
Product listAre you struggling with inconsistent Eph receptor targeting or delayed therapeutic validation? Creative Biolabs' EPHA2 specific Neutra™ antibody products overcome these challenges through advanced recombinant DNA platforms and epitope-directed engineering, enabling rapid development of high-affinity antibodies for functional studies and therapeutic pipelines.
Introduction to EPHA2
EPH Receptor A2 (EPHA2), a member of the receptor tyrosine kinase (RTK) family, regulates cell-cell communication, adhesion, and tissue patterning. Overexpressed in malignancies, EPHA2 drives oncogenic signaling through ligand-dependent and ligand-independent mechanisms. Its dual role as both a tumor suppressor and promoter, depending on activation context, makes it a compelling therapeutic target.
- Structure
EPHA2 features a conserved extracellular domain with two fibronectin type III repeats, a cysteine-rich region, and a cytoplasmic tyrosine kinase domain. The transmembrane segment anchors the receptor, while the C-terminal SAM (sterile alpha motif) mediates oligomerization. Phosphorylation at tyrosine residues Y588 and Y594 initiates downstream signaling cascades. Notably, EPHA2's conformational flexibility enables distinct signaling outcomes: ligand binding (ephrin-A) induces kinase activation and tumor-suppressive effects, while ligand-independent phosphorylation (e.g., S897) promotes metastasis.
- Related Signaling Pathways
EPHA2 interacts with RAS-MAPK, PI3K-AKT, and FAK pathways to modulate cell migration, survival, and angiogenesis. In cancer, dysregulated EPHA2 activates integrin-mediated adhesion, enhancing invasive potential. Cross-talk with EGFR and VEGF amplifies pro-tumorigenic signals, while downstream Rho-GTPase activation reorganizes the cytoskeleton to facilitate metastasis.
Fig.1 EphA2 signal transduction in normal and cancer cells.1
- Associated Pathologies
EPHA2 overexpression correlates with poor prognosis in breast, lung, prostate, and ovarian cancers. It fuels resistance to chemotherapy and radiation by upregulating anti-apoptotic proteins. Beyond oncology, EPHA2 contributes to pathological angiogenesis in age-related macular degeneration and fibrotic disorders via aberrant Ephrin-A1 signaling.
Applications of Anti-EPHA2 Neutralizing Antibodies
- Therapeutic Intervention in Solid Tumors
Neutralizing antibodies suppress EPHA2-driven metastasis by inhibiting ligand-independent signaling. Preclinical models show enhanced efficacy when combined with chemotherapy, reducing tumor burden in triple-negative breast cancer and glioblastoma, presenting a promising, targeted strategy against aggressive malignancies.
- Diagnostic and Prognostic Biomarker Development
High-sensitivity ELISA kits utilizing EPHA2 antibodies quantify receptor levels in serum or tissue biopsies, aiding in early cancer detection and monitoring treatment resistance, facilitating the personalization of oncology treatment plans.
- Targeted Drug Delivery Systems
Antibody-drug conjugates (ADCs) linked to cytotoxic payloads selectively deliver therapeutics to EPHA2-overexpressing cells, minimizing off-target effects in healthy tissues, thereby improving the therapeutic index significantly.
- Angiogenesis Modulation
In retinal diseases, anti-EPHA2 antibodies inhibit pathological blood vessel formation by blocking Ephrin-A1/EPHA2 interactions, offering a novel approach for anti-angiogenic therapy, potentially benefiting patients with Wet AMD or diabetic retinopathy.
Our Anti-EPHA2 Antibodies
Creative Biolabs' neutralizing antibodies selectively target EPHA2's extracellular ephrin-binding domain or the ligand-independent S897 phosphorylation site. Our monoclonal antibodies demonstrate sub-nanomolar affinity, validated in blocking EPHA2 clustering, internalization, and downstream oncogenic signaling. Engineered for minimal cross-reactivity with other Eph receptors, these antibodies are optimized for therapeutic development, in vivo imaging, and companion diagnostics.
Creative Biolabs offers EPHA2 specific antibody products, which are validated in flow cytometry, IHC, and functional assays, to fast-track translational discoveries. Contact our team today to discuss customized solutions for your oncology or fibrosis projects.
REFERENCE
- Giordano, Giorgia, et al. "Targeting the EphA2 pathway: could it be the way for bone sarcomas?." Cell Communication and Signaling 22.1 (2024): 433. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s12964-024-01811-7
